Julia Foldi

Nov 8, 2024 | nature.com | Fangyuan Chen |George Tseng |Julia Foldi |Adrian Lee

AbstractUnderstanding interplay of breast cancer and microenvironment is critical. Here we identified two transcriptomic subtypes and five immune infiltration patterns from RNA-seq and multiplex immunohistochemistry from 21 ER + /HER2- ILCs. We found proliferative subtype associated with increased suppressive immune infiltration, and defined a signature associated with lower proliferative, pro-inflammatory TAM infiltration, and improved survival in ER+ breast cancer.

Jun 4, 2024 | onclive.com | Julia Foldi

CommentaryVideoJune 4, 2024Author(s):Julia Foldi, MD, PhD, discusses the utility of of T-DXd and sacituzumab govitecan in the treatment of metastatic HER2-low and triple-negative breast cancer.

Jun 4, 2024 | onclive.com | Julia Foldi

CommentaryVideoJune 4, 2024Author(s):Julia Foldi, MD, PhD, discusses the evolving role of antibody-drug conjugates in the treatment paradigm for metastatic HER2-positive breast cancer.

May 29, 2024 | onclive.com | Julia Foldi

May 29, 2024Julia Foldi, MD, PhD, discusses interstitial lung disease associated with the use of T-DXd in HER2+ breast cancer. Julia Foldi, MD, PhD, assistant professor, medicine, Hematology/Oncology, Department of Medicine, University of Pittsburg Medical Center (UPMC), breast medical oncologist, UPMC Hillman Cancer Center, discusses interstitial lung disease (ILD) associated with the use of fam-trastuzumab deruxtecan-nxki (Enhertu; T-DXd) in patients with HER2-positive breast cancer.

Apr 17, 2024 | onclive.com | Julia Foldi

Julia Foldi, MD, PhD, assistant professor of medicine, Hematology/Oncology, Department of Medicine, University of Pittsburg Medical Center (UPMC), University of Pittsburg Medical Center, breast medical oncologist, UPMC Hillman Cancer Center, discusses the evolving role of fam-trastuzumab deruxtecan-nxki (Enthertu; T-DXd) in the treatment of metastatic HER2-positive breast cancer.